APYX earnings analysis
What we found in APYX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Apyx Medical Corporation reported strong Q1 2026 results with revenue of $12.5 million, surpassing expectations of $10.9 million, and a narrower EPS loss of $0.05 compared to an estimated loss of $0.11. The surgical aesthetics segment saw significant growth, prompting a raise in full-year revenue guidance to $59-$60 million, indicating positive momentum in their product lineup.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Exceeds Estimates
- Q1 2026 revenue reached $12.5 million, exceeding the expected $10.9 million by 14.3%.
- Narrowed EPS Loss
- Diluted EPS loss was reported at $0.05, outperforming the estimated loss of $0.11 by 54.5%.
- Segment Growth in Surgical Aesthetics
- Sales in the Surgical Aesthetics segment grew by 36.1%, totaling $10.7 million in Q1 2026.
- Improved Gross Margin
- Gross margin increased to 63.5%, up from 60.1% year-over-year.
- International Sales Surge
- International sales increased by 62.9%, making up 35.1% of total revenue.
- Increased Guidance for FY2026
- Revenue guidance raised to $59-$60 million from a previous $57.5-$58.5 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Net Losses
- The company continues to incur net losses, totaling approximately $0.6 million in Q1 2026.
- Operational Funding Dependence
- Management noted that operational funding is contingent on product sales and potential future financing options.
- Market Competition Risks
- Increased competition within the aesthetic market due to GLP-1 medications potentially affecting growth.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.05
- Gross margin
- 63.5%
- Segment
- Surgical Aesthetics: $10.7M
- Segment
- OEM: $1.8M
What they said about what is next.
Raised fiscal year 2026 revenue guidance from $57.5-$58.5 million to $59-$60 million.
The filing reads better than the one before it.
What came before.
- 10-K · March 10, 2026
- Apyx reported accelerating commercial traction in 2025 driven by the AYON launch and higher product sales, generating record Q4 revenue of $19.2M and implied full-year revenue of about $52.0M. Cost actions reduced…
- 10-Q · November 6, 2025
- Apyx reported Q3 sales of $12.877M (up $1.390M or ~12.1% YoY from $11.487M) with gross profit of $8.297M and gross margin expanding to ~64.4%. Operating loss narrowed to $(832)k (vs $(3.635)M a year ago) and diluted…
- 10-Q · August 7, 2025
- Apyx reported Q2 2025 sales of $11.373M and GAAP diluted EPS of $(0.09), roughly in line with consensus but down versus Q2 2024. Profitability and cash flow are improving: gross margin expanded to 62.3% and operating…
- 10-Q · May 9, 2024
- Apyx reported revenue of $10.244M for Q1 2024, down 15.6% year-over-year, driven by a 23.1% decline in Advanced Energy sales (to $7.453M) partially offset by a 13.8% increase in OEM sales (to $2.791M). Gross profit…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing APYX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever